- Home
- FHTX vs LEGT Comparison
FHTX vs LEGT Comparison
Compare FHTX & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- LEGT
- Stock Information
- Founded
- FHTX 2015
- LEGT 2023
- Country
- FHTX United States
- LEGT United States
- Employees
- FHTX N/A
- LEGT N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- LEGT
- Sector
- FHTX Health Care
- LEGT
- Exchange
- FHTX Nasdaq
- LEGT Nasdaq
- Market Cap
- FHTX 246.6M
- LEGT 278.6M
- IPO Year
- FHTX 2020
- LEGT 2024
- Fundamental
- Price
- FHTX $5.21
- LEGT $10.85
- Analyst Decision
- FHTX Strong Buy
- LEGT
- Analyst Count
- FHTX 6
- LEGT 0
- Target Price
- FHTX $11.83
- LEGT N/A
- AVG Volume (30 Days)
- FHTX 270.9K
- LEGT 171.2K
- Earning Date
- FHTX 11-05-2025
- LEGT 01-01-0001
- Dividend Yield
- FHTX N/A
- LEGT N/A
- EPS Growth
- FHTX N/A
- LEGT N/A
- EPS
- FHTX N/A
- LEGT 0.33
- Revenue
- FHTX $24,518,000.00
- LEGT N/A
- Revenue This Year
- FHTX $42.43
- LEGT N/A
- Revenue Next Year
- FHTX $14.77
- LEGT N/A
- P/E Ratio
- FHTX N/A
- LEGT $33.03
- Revenue Growth
- FHTX N/A
- LEGT N/A
- 52 Week Low
- FHTX $2.95
- LEGT $10.26
- 52 Week High
- FHTX $8.45
- LEGT $11.25
- Technical
- Relative Strength Index (RSI)
- FHTX 63.51
- LEGT 44.94
- Support Level
- FHTX $4.63
- LEGT $10.81
- Resistance Level
- FHTX $5.69
- LEGT $10.90
- Average True Range (ATR)
- FHTX 0.40
- LEGT 0.09
- MACD
- FHTX 0.12
- LEGT -0.02
- Stochastic Oscillator
- FHTX 74.95
- LEGT 32.81
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.